CRL Charles River Laboratories International Inc

Price (delayed)

$290.305

Market cap

$13.86B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.79

Enterprise value

$16.69B

?
Relative Growth: Rel. Growth: 9
Relative Strength: Rel. Strength: 94
Relative Valuation: Rel. Valuation: 16
Relative Profitability: Rel. Profitability: 22

Charles River Laboratories International, Inc. is a global provider of solutions, which accelerate the early-stage drug discovery and development process. The focus of its business is in vivo biology; its ...

Highlights
The EPS fell by 29% QoQ
The net income has declined by 29% since the previous quarter

Key stats

What are the main financial stats of CRL

CRL stock price

How has the Charles River Laboratories International stock price performed over time
Intraday
-0.5%
1 week
-2.06%
1 month
25.74%
1 year
78.84%
YTD
45.53%
QTD
28.01%

Financial performance

How have Charles River Laboratories International's revenue and profit performed over time
Revenue
$4B
Gross profit
$1.31B
Operating income
$90.14M
Net income
-$238.46M
Gross margin
32.7%
Net margin
-6%
The operating margin rose by 35% QoQ but it fell by 26% YoY
Charles River Laboratories International's net margin has decreased by 30% QoQ
The net income has declined by 29% since the previous quarter
CRL's operating income is up by 28% QoQ but it is down by 28% YoY

Price vs fundamentals

How does CRL's price correlate with its fundamentals

Growth

What is Charles River Laboratories International's growth rate over time

Valuation

What is Charles River Laboratories International stock price valuation
P/E
N/A
P/B
4.92
P/S
3.49
EV/EBIT
N/A
EV/EBITDA
76.47
EV/Sales
4.17
The EPS fell by 29% QoQ
The price to book (P/B) is 71% higher than the last 4 quarters average of 2.9 and 30% higher than the 5-year quarterly average of 3.8
The equity has declined by 15% year-on-year and by 3.4% since the previous quarter
The P/S is 59% higher than the last 4 quarters average of 2.2 and 21% higher than the 5-year quarterly average of 2.9

Efficiency

How efficient is Charles River Laboratories International business performance
The ROS has shrunk by 183% YoY and by 33% QoQ
The company's return on invested capital has shrunk by 182% YoY and by 27% QoQ
The ROE has contracted by 35% from the previous quarter
The company's return on assets fell by 28% QoQ

Dividends

What is CRL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CRL.

Financial health

How did Charles River Laboratories International financials performed over time
The company's total assets is 62% higher than its total liabilities
The total liabilities rose by 12% YoY but it fell by 2.1% QoQ
The quick ratio has declined by 9% year-on-year and by 2.4% since the previous quarter
Charles River Laboratories International's debt is 7% higher than its equity
Charles River Laboratories International's debt to equity has increased by 29% YoY and by 2.9% from the previous quarter
The equity has declined by 15% year-on-year and by 3.4% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.